This issue is devoted to molecular imaging in the context of personalized medicine. Recent advances in biology, particularly genomic and expression screens, have made it possible to hope that treatment can be matched very specifically to the patient's disease, as characterized at the molecular level. In oncology, where hopes for personalized medicine are perhaps highest, tumors will be treated based on the specific mutations that drive their unrestrained growth, rather than on their site of origin. For all branches of medicine, there is also the potential for matching drug dosage to the individual's drug metabolism profile, established through genetic analysis.
Along with genomic information, molecular imaging will be crucial in the development of personalized medicine. Molecular imaging-essentially any imaging procedure that delivers some information on a disease state, beyond the purely anatomical-is an incredibly diverse area of research, covering every disease state and imaging modality, with astonishing innovation in developing novel imaging agents. However, there are three aims that commonly emerge in the literature: to image some physiological/biological state that will be diagnostic/predictive; to observe treatment response; and to image the accumulation of drug in the lesion, an approach known as theranostics.
Appropriately, all these aims are represented in the six articles featured here. Dr. X. Li et al. (Shenyang, China) report the successful production of a 68 Ga labeled rhodamine based probe for PET imaging of mitochondrial potential in tumors, with the biology of probe uptake still to be clarified. Dr. W. Zhou et al. (Hohhot, China) We hope that the reader will find something stimulating in this selection from an exciting and rapidly expanding area of research.
